Clinical Trials Logo

Gastrointestinal Stromal Tumors clinical trials

View clinical trials related to Gastrointestinal Stromal Tumors.

Filter by:

NCT ID: NCT06326346 Not yet recruiting - Clinical trials for Gastrointestinal Stromal Tumors

GIST Oral Paciltaxel(Liporaxel)

Start date: June 1, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate safety and efficacy of Liporaxel for patients with GIST who failed on prior standard treatments, including imatinib, sunitinib, and regorafenib, and with low P-glycoprotein expression.

NCT ID: NCT06321055 Not yet recruiting - Clinical trials for Advanced Gastrointestinal Stromal Tumor

An Observational Study to Learn More About Treatment With Regorafenib in People With Advanced Gastrointestinal Stromal Tumors in the United States

Start date: March 20, 2024
Phase:
Study type: Observational

This is an observational study in which data already collected from people with advanced gastrointestinal stromal tumors are studied. In this observational study data are collected from participants who have private insurance or Medicare and who had started regorafenib treatment. Gastrointestinal stromal tumor (GIST) is a type of cancer that most commonly originates from the stomach or small intestine. Advanced means that the cancer has spread to other parts of the body. The study drug, regorafenib, is already approved for doctors to prescribe to people with GIST. Regorafenib works by blocking certain proteins that cause the growth of cancer cells. Regorafenib is recommended as the third choice of treatment for patients after imatinib and sunitinib have stopped working or have caused side effects that are too severe to continue the treatment. In addition, it is also the recommended first choice of treatment in people with GIST who had low levels of protein called succinate dehydrogenase (SDH) protein. This condition is called SDHdeficient GIST. However, doctors might sometimes give it in a different order. To better understand the treatment patterns with regorafenib for GIST, more knowledge is needed about its use in the real world. The participants in this study had started treatment with regorafenib as part of their regular care from their doctors. The main purpose of this study is to learn more about the use of regorafenib treatment among people with advanced GIST who have private insurance or Medicare in the United States. To do this, researchers will collect information on: Duration of treatment with regorafenib (also known as duration of therapy) The length of time it took for participants to switch to another GIST treatment after starting regorafenib (also known as time to next therapy) The data will come from the participants' information stored in a database, called Merative MarketScan for people in the United States. Data collected will be from April 2002 to September 2023. Researchers will track the data of people with GIST who started regorafenib and will follow them for at least 28 days. In this study, only available data are collected. No visits or tests are required as part of this study.

NCT ID: NCT06208748 Not yet recruiting - Clinical trials for Gastrointestinal Stromal Tumors

SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST

Start date: March 2024
Phase: Phase 2
Study type: Interventional

This is an open label, single arm, phase 2 trial investigating bezuclastinib plus sunitinib in patients with GIST who have previously progressed on sunitinib.

NCT ID: NCT05970900 Not yet recruiting - Clinical trials for Gastrointestinal Stromal Tumor of Rectum

Preoperative Imatinib Mesylate Combined With Rectal-sparing Surgery in Patients With c-KIT Gene-mutant Rectal GIST

PIRKER
Start date: October 1, 2023
Phase: Phase 3
Study type: Interventional

Prior to the implementation of preoperative imatinib mesylate therapy, a considerable percentage (ranging from 34.5% to 67.5%) of individuals diagnosed with rectal gastrointestinal stromal tumors (GIST) underwent abdominoperineal resection (APR), a surgical procedure that involved the removal of the anus and necessitated a permanent colostomy. This study aims to investigate the safety and viability of an organ-preserving approach involving preoperative imatinib mesylate treatment in conjunction with local resection for rectal GIST, specifically targeting patients with c-KIT gene mutations.

NCT ID: NCT05938309 Recruiting - Clinical trials for Gastrointestinal Stromal Tumors

A Cohort Study on the Safety of Laparoscopic Resection of 5cm or Larger Gastric Gastrointestinal Stromal Tumors

Start date: May 1, 2023
Phase:
Study type: Observational

The purpose of this study is to explore the safety of laparoscopic resection of 5cm or larger gastric gastrointestinal stromal tumors

NCT ID: NCT05905887 Recruiting - Clinical trials for Gastrointestinal Stromal Tumors

Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor

Start date: September 6, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of rivoceranib and paclitaxel combination therapy in patients with P-glycoprotein overexpressing GIST who failed standard treatment with imatinib, sunitinib, and regorafenib.

NCT ID: NCT05867901 Recruiting - Clinical trials for Gastrointestinal Stromal Tumors

Clinical Research of Drug Holiday Based on MRD Detection in GIST Patients at High Risk of Recurrence

Start date: June 1, 2023
Phase:
Study type: Observational

This study is aimed: - to evaluate the dynamic monitoring value of MRD detection for postoperative recurrence in high-risk GIST patients; - to evaluate the effect of drug holiday mode based on MRD detection on progression-free Survival (PFS) and/or overall survival (OS) after drug withdrawal for high-risk GIST patients who have achieved disease control after long-term use of imatinib; ③ to investigate the response rate of imatinib re-use in patients who developed disease progression after drug withdrawal; ④ to explore whether the "drug holiday" treatment mode based on MRD detection could delay the occurrence of secondary imatinib resistance mutations for high-risk GIST patients with long-term use of imatinib after surgery.

NCT ID: NCT05800106 Completed - Clinical trials for Renal Cell Carcinoma

A Bioequivalence Study of Sunitinib Malate Capsules.

Start date: December 4, 2018
Phase: Phase 1
Study type: Interventional

A randomized, open, two-period, two-sequence crossover trial design used to assess the pharmacokinetics and safety of Sunitinib Malate Capsules in healthy volunteers under fed condition, and compare the bioequivalence of Sunitinib Malate Capsules produced by Pfizer and Chia Tai Tianqing Pharmaceutical Group Co., Ltd, respectively.

NCT ID: NCT05751733 Recruiting - Clinical trials for Gastrointestinal Stromal Tumors

Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST

Start date: February 1, 2023
Phase: N/A
Study type: Interventional

The goal of this Mesylate apatinib versus standard second-line TKI in the treatment of advanced gastrointestinal stromal tumors: a randomized, open, controlled, single-center clinical study is to explore the efficacy and safety of Apatinib compared with second-line treatment in advanced GIST patients with first-line TKI failure. The main questions it aims to answer are: - To explore the efficacy and safety of Apatinib compared with standard second-line treatment for GIST with advanced first-line TKI failure. - To explore the expression level and MVD value of VEGFR2 in GIST, and to explore the relationship between the expression level and the location, size, mitotic image and recurrence risk grading of GIST. Patients with advanced GIST were randomly included in the trial group and the control group at a ratio of 1:1.